ELVITEGRAVIR: 211 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
211
Total FAERS Reports
8 (3.8%)
Deaths Reported
33
Hospitalizations
211
As Primary/Secondary Suspect
1
Life-Threatening
Sep 24, 2014
FDA Approved
Discontinued
Status
FDA Application: 203093 ·
Patent Expires: Oct 26, 2026 · First Report: 2012 · Latest Report: 20230614
What Are the Most Common ELVITEGRAVIR Side Effects?
#1 Most Reported
Pathogen resistance
40 reports (19.0%)
#2 Most Reported
Virologic failure
38 reports (18.0%)
#3 Most Reported
Foetal exposure during pregnancy
31 reports (14.7%)
All ELVITEGRAVIR Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Pathogen resistance | 40 | 19.0% | 0 | 1 |
| Virologic failure | 38 | 18.0% | 0 | 1 |
| Drug resistance | 31 | 14.7% | 0 | 1 |
| Foetal exposure during pregnancy | 31 | 14.7% | 2 | 1 |
| Viral mutation identified | 29 | 13.7% | 0 | 1 |
| Drug ineffective | 18 | 8.5% | 3 | 5 |
| Exposure during pregnancy | 18 | 8.5% | 0 | 1 |
| Immune reconstitution inflammatory syndrome | 16 | 7.6% | 0 | 7 |
| Treatment failure | 16 | 7.6% | 0 | 0 |
| Treatment noncompliance | 16 | 7.6% | 0 | 3 |
| Renal dysplasia | 15 | 7.1% | 0 | 0 |
| Blood hiv rna increased | 13 | 6.2% | 0 | 0 |
| Single functional kidney | 13 | 6.2% | 0 | 0 |
| Renal aplasia | 11 | 5.2% | 0 | 0 |
| Abortion spontaneous | 8 | 3.8% | 0 | 0 |
| Drug intolerance | 8 | 3.8% | 0 | 1 |
| Foetal exposure during delivery | 8 | 3.8% | 0 | 0 |
| Premature labour | 8 | 3.8% | 0 | 0 |
| Cholestasis of pregnancy | 7 | 3.3% | 0 | 0 |
| Depression | 7 | 3.3% | 0 | 2 |
Who Reports ELVITEGRAVIR Side Effects? Age & Gender Data
Gender: 38.8% female, 61.2% male. Average age: 42.4 years. Most reports from: US. View detailed demographics →
Is ELVITEGRAVIR Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2012 | 1 | 0 | 1 |
| 2013 | 4 | 0 | 2 |
| 2014 | 1 | 0 | 0 |
| 2015 | 6 | 0 | 3 |
| 2016 | 10 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 1 |
| 2021 | 2 | 0 | 0 |
| 2022 | 9 | 0 | 0 |
| 2023 | 2 | 0 | 0 |
What Is ELVITEGRAVIR Used For?
| Indication | Reports |
|---|---|
| Hiv infection | 154 |
| Product used for unknown indication | 27 |
| Antiretroviral therapy | 7 |
ELVITEGRAVIR vs Alternatives: Which Is Safer?
ELVITEGRAVIR vs EMAPALUMAB
ELVITEGRAVIR vs EMAPALUMAB-LZSG
ELVITEGRAVIR vs EMEND
ELVITEGRAVIR vs EMICIZUMAB
ELVITEGRAVIR vs EMICIZUMAB-KXWH
ELVITEGRAVIR vs EMPAGLIFLOZIN
ELVITEGRAVIR vs EMPAGLIFLOZIN\LINAGLIPTIN
ELVITEGRAVIR vs EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN
ELVITEGRAVIR vs EMPAGLIFLOZIN\METFORMIN
ELVITEGRAVIR vs EMTRICITABINE
Official FDA Label for ELVITEGRAVIR
Official prescribing information from the FDA-approved drug label.